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ABSTRACT
Objectives: The expected lifetime of a health technology is a critical
parameter in value of information analysis and in two methodologies for
cost-effectiveness analysis which have recently been suggested. The ﬁrst
method allows for the possibility that a superior technology will become
available in the future. The second advocates modeling both the prevalent
and all future incident patient cohorts. Unfortunately, for value of infor-
mation analysis, the period of time over which information about the
decision problem would be useful is very uncertain, and existing estimates
are seemingly arbitrary. Furthermore, there is very little literature on the
historical lifetimes of technologies. Here, I quantify and analyze the his-
torical lifetimes of drugs in England. I then apply this information to
inform the value of further research and the cost-effectiveness of health
technologies.
Methods: A Weibull regression model was ﬁtted to the historical drug
lifetimes of 455 drugs. These represented all British National Formulary
drugs in England which were launched from 1981 to 2007, and which did
not have very low sales volumes.
Results: The mean drug lifetime was 57 years (95% conﬁdence interval
39–79 years), and the median was 46 years (35–60 years). Drugs with low
sales volumes tended to have shorter lifetimes. Under certain assumptions,
the ratio of population level to per-year expected value of information is
21. Drug lifetimes are used to parameterize the two models of cost-
effectiveness.
Conclusions: The distribution function of the historical lifetimes of drugs
can inform suitable time horizons for: 1) value of information; and 2)
cost-effectiveness analyses related to drugs.
Keywords: cost-effectiveness analysis, decision modeling, ICER, technol-
ogy assessment, time horizon, value of information analysis.
Introduction
In this study, I calculate and analyze the historical lifetimes of
drugs in England over the period 1980 to 2007. I apply the
estimates of drug lifetimes to two areas: to inform the time
horizon for value of information analysis of drugs, and to cost-
effectiveness analysis.
I am aware of just one study, by Danzon and Kim [1], which
is related to the estimation of the historical lifetimes of drugs.
They investigated the sales volume of drugs at the level of the
individual chemical, and found that the volume of sales of indi-
vidual drugs over time is generally -shaped [1]. The volume of
drugs sold typically increases in the ﬁrst decade after drug
launch, reﬂecting the diffusion of the new drug after launch. The
volume in the second decade after launch, typically after patent
expiry, declines as patients switch to newer, more effective, drugs
[1,2]. They found that the sales volume of “global” chemicals
(deﬁned as molecules that were available in all seven countries
they studied) on average peaked at about 20 to 30 years in the
UK, and generally slightly earlier in the other countries consid-
ered: Canada, Germany, France, Italy, Japan, and USA [1].
Although they do not present data on the typical lifetimes of
drugs, their ﬁndings suggest that lifetimes are typically more than
30 years. Nevertheless, the generality of their ﬁndings is limited
by the fact that they analyzed only high volume, “global” chemi-
cals, and that their data are now rather out of date, relating to the
period 1981 to 1992.
Value of Information and Drug Lifetimes
Value of information analysis provides an analytic framework to
establish the value of acquiring additional information to inform
a decision problem [3]. It is increasingly being used in health
technology assessment [4]. For example, the expected value of
perfect information (EVPI) has been used to establish a necessary
condition for conducting further research and for identifying
research priorities [5,6].
Methods for estimating the value of information are
described in full elsewhere [7]. Therefore, here, I outline only the
main points. The cost-effectiveness of a treatment option j can be
expressed in terms of net beneﬁt, NBj = lQj -Cj, where l is the
cost-effectiveness threshold, and Qj and Cj are the discounted
health beneﬁt and cost, respectively. The optimal decision with
current information is to choose the treatment with the
maximum expected net beneﬁt maxjEqNB(j,q) [8]. With perfect
information, the parameters q, used to estimate Qj and/or Cj, are
known, hence the decision-maker should select the treatment
that maximizes the net beneﬁt given the particular value of q,
maxjNB(j,q). Nevertheless, the net beneﬁt NBj is uncertain
because some model parameters, q, are uncertain. The EVPI for
an individual patient is the difference between the expected value
of the decision made with perfect information about the q and
the decision made given uncertainty in q [7]:
EVPI E NB j E NB jj j= ( ) − ( )θ θθ θmax ,, max
This can be generalized to the value of information of particular
groups of parameters in the decision problem (EVPPI) and the
expected value of sample information [7–9]. All these measures
of the value of information must consider the future patient
population that can beneﬁt from it. The population expected
value of information (PEVPI) is typically calculated based on a
function of the effective lifetime of the treatment, the period over
which information about the decision will be useful [T], the
population incidence at time t over this period (It), and the
discount rate (r). For example, the PEVPI is the discounted sum
of the EVPI per patient [7];
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It is very important to estimate the time horizon T as accurately
as possible because this is an important determinant of PEVPI
(Fig. 1). Indeed, at a discount rate of 3.5%, the value currently
used in England [10], assuming equal population incidence each
year, the population EVPI is about 29 times greater than the
per-year EVPI (deﬁned as the EVPI per patient multiplied by the
population incidence per year) as T tends to inﬁnity (Equation 1;
Fig. 1). Clearly, the time horizon has a substantial impact on
estimates of PEVPI. Of course, the choice of T might not change
a decision to conduct research, but in some circumstances it will.
If additional research costs more than 29 times the per-year
EVPI, then it will not be cost-effective to conduct this research.
Notice that we do not need to specify T accurately for times
greater than about 50 years, because at such times, the ratio of
population to per-year EVPI is close to the asymptote of 29.
Unfortunately, the time horizon is very uncertain [11].
Indeed, existing estimates, typically about 10 to 20 years, are
seemingly arbitrary [12]. These approaches implicitly use the
time horizon as a proxy for future changes in technology, prices,
and information. Given the dearth of empirical evidence for T,
recent methodological literature recommends using ﬁnite time
horizons with population EVPI presented for a range of possible
values of T [9,12,13].
I am aware of just one empirical estimate of the time horizon,
given by Hall and Platell [14], and discussed by Philips et al. [12]
in the context of the value of information. Hall and Platell [14]
investigated the relationship between the probability that state-
ments regarding general surgery are still considered true as a
function of the time from when the statement was made. They
estimated the half-life of the truth of such statements as 45 years,
which assuming an exponential distribution, gives a mean of
64 years.
Clearly, there will be uncertainty in any estimate of the time
horizon T, and this should be included in estimates of population
EVPI. It is especially important to allow for uncertainty because,
given discounting, the population EVPI assuming the mean value
of T does not necessarily equal the EVPI weighted according to
the range of values of T [12]. This is because lower than expected
sampled values of T reduce PEVPI substantially, but higher than
expected values increase PEVPI more modestly (Fig. 1).
Some types of information may apply speciﬁcally to a single
health technology decision (e.g., the mean survival of patients
taking a certain drug). Other information may be more general,
for example, concerning the natural history of a disease [12]. A
shorter time horizon may be more appropriate in the former case
and a longer time horizon in the latter case. In this article, I
analyze the lifetimes of pharmaceutical in England in the past. I
argue that this information is more appropriate for estimating
the time horizon in the former case (i.e., for information con-
cerning a single drug).
Cost-Effectiveness Analysis and Drug Lifetimes
Estimates of the future lifetimes of drugs are useful to inform two
methodological frameworks for cost-effectiveness analysis that
have been suggested recently: those of Salomon et al. [2] and
Hoyle and Anderson [15]. These frameworks both satisfy the
National Institute for Health and Clinical Excellence (NICE)
guidance [10] for cost-effectiveness analysis that “the time
horizon should be sufﬁcient to reﬂect important cost and beneﬁt
differences between the technologies being compared.”
When a decision is uncertain and there is evidence that guid-
ance may be reversed in the future, for example, if new evidence
suggests that the technology is not cost-effective or if another
technological development makes it obsolete, then it may be
most cost-effective to wait until the uncertainties are resolved or
until additional research is reported [2,13,16] An option-pricing
approach may be appropriate, in which the incremental cost-
effectiveness ratio (ICER) is adjusted to reﬂect the magnitude of
uncertainty in parameter values, the extent to which decision
deferral is possible, and the extent to which the decision to
implement is irreversible [16]. Salomon et al. [2] suggest the
following methodology to allow for the possibility that a further
technology may be introduced in the future. Suppose we compare
the cost-effectiveness of a new technology A against an existing
technology (or indeed, no treatment). There are then two
options: either do or do not adopt technology A. Salomon et al.
[2] suggest that we could model a third option of deferred treat-
ment with some further, more effective technology B, which is
likely to be introduced several years in the future. The third
option is then: do not adopt technology A, but wait several years
and then adopt technology B. To model this option, we can
either: 1) assume we know with complete certainty the effective-
ness and cost of technology B, and when it will become available;
or 2) allow for uncertainty in these quantities by stochastic
modeling. Now, this article informs the expected lifetime of
technology A, assuming that the technology is a drug, and that
the lifetime of technology A is typical of the historical lifetimes of
drugs in England. We could then estimate the date of introduc-
tion of the new, improved technology B as the expected lifetime
of technology A (i.e., technology B is introduced when technol-
ogy A is phased out).
In the second methodological framework, Hoyle and Ander-
son [15] have recently noted that economic evaluations of health
technologies typically simulate only the prevalent cohort or the
current incident cohort of patients. The prevalent cohort is
deﬁned as those patients eligible for the new technology at the
time the technology is introduced [15]. Any given patient will be
eligible for the new technology from the time when the technol-
ogy is ﬁrst clinically appropriate (e.g., just diagnosed with mul-
tiple sclerosis and eligible for drug treatment, or when ﬁrst
eligible for a hip replacement) until the time when the new
technology is no longer appropriate (e.g., patient dies, or the
disease has reached such a severe state that the drug is no longer
effective, or the patient is too old to receive a hip replacement).
The incident cohort starting t years in the future (i.e., t years after
the date of introduction of a technology) is deﬁned as comprising
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Figure 1 Population expected value of perfect information (EVPI) as a function
of information time horizon T calibrated so that the per-year EVPI = 1. The
relationship is obtained from Equation 1, with discount rate = 3.5%.The vertical
lines represent the lower 95% conﬁdence interval (CI), the mean, and the upper
95% CI of the mean drug lifetime over all drugs (see Results).
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those patients who ﬁrst become eligible for the new technology
(e.g., diagnosed) t years in the future [15]. The prevalent cohort
is small relative to the incident cohort when a technology is
appropriate only for a short time window in the life of a patient,
for example, for drugs or medical devices used to treat acute
conditions, or for screening people at certain ﬁxed ages [15].
When the discount rates for costs and beneﬁts differ, as cur-
rently in The Netherlands and Belgium [15], all future incident
cohorts should be modeled, because the ICER (cost per QALY or
cost per life-year) assuming all future incident cohorts are differ-
ent to the ICER assuming just a single incident cohort (Equa-
tion 2) [15]. In particular, when the discount rate for beneﬁts is
lower than for costs, the ICER for all future incident cohorts is
lower than the ICER for the ﬁrst incident cohort. Next, when the
prevalent cohort is large compared to a single incident cohort,
both the prevalent cohort and all future incident cohorts should
be modeled [15]. Now, suppose this is not true, we ignore the
prevalent cohort [15]:
ICER
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where:
• nt = number of patients eligible for the new technology at
the start of the incident cohort starting t years in the future,
relative to the number of eligible patients at the start of the
ﬁrst year;
• pt = probability an eligible patient is given the new technol-
ogy t years in the future;
• vC, vB = costs and beneﬁts discount factors over a year;
• T = expected lifetime of new technology in years.
When either ntpt is equal for all t, or follows a -shaped qua-
dratic curve over time, as is often the case with drug sales, as
described above [1], n p vt t t
t
T
=
∑
0
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I suggest that the expected lifetime of the technology, T, and the
uncertainty in T, where the technology is a drug, can be esti-
mated by the historical lifetimes of drugs as presented in this
study. The uncertainty in T can be used for the probabilistic
sensitivity analysis.
The objectives of this study are to: 1) estimate the distribution
function of the historical lifetimes of drugs in England, for drugs
launched from 1981 to 2007; and 2) use this information to
parameterize models of the value of information and cost-
effectiveness of drugs.
Methods
Data
I analyzed the prescription data from the Prescription Cost
Analysis for England [17] for the years 1980 to 2007. Prescrip-
tions written by general medical practitioners in England repre-
sent the vast majority of prescriptions included [17], and account
for the great majority, 75%, of pharmaceutical expenditure in the
NHS [18]. See Online Appendix for further details of the data.
I analyzed the number of prescriptions written over time at the
level of the British National Formulary (BNF) Chemical, because
this is the level at which cost-effectiveness analyses are conducted
by NICE in England and Wales, and by similar bodies in other
countries [19]. There are typically several preparations within
each BNF Chemical, some branded and some generic. When a new
chemical is launched, there may be just a single branded prepara-
tion. Later, when the patent expires, generic versions may become
available. Before data analysis, it was necessary to correct the data
for two types of inconsistency. First, sometimes the same chemical
is spelled slightly differently (e.g., amlodipine besilate =
amlodipine besylate, amoxicillin = amoxycillin, beclometasone
dipropionate = beclomethasone dipropionate). Second, some-
times the same chemical is recorded under completely different
names (e.g., alimemazine tartrate = trimeprazine tartrate, dosul-
epin hydrochloride = dothiepin hydrochloride).
Estimation of Drug Lifetimes
The lifetime of each chemical was deﬁned as the latest year for
which prescriptions for the chemical were written minus the
launch year of the chemical. As Danzon and Kim [1], I deﬁned
the launch year of a chemical in England as the earliest year for
which any prescriptions for that chemical were written in
England. I analyzed the number of prescriptions written for all
455 chemicals launched from 1981 to 2007. If prescriptions were
written in the latest year (2007), the lifetime of the chemical was
recorded as being right censored. I discarded those chemicals
with very low sales volumes, in particular those with less than
5000 prescriptions written in all years. Were these chemicals
included, their estimated lifetimes may be too low, because of the
low sales volumes, preparations may have prescriptions written
in some years, but not recorded in the database.
I hypothesized that the lifetimes of chemicals would be inﬂu-
enced by three factors: the year of chemical launch, the “sales
volume” of the chemical, and the therapeutic area, deﬁned as the
BNF Chapter. Therefore, a linear survival regression model of the
lifetime of each chemical was ﬁtted, with launch year, log(average
number of prescriptions per year + 1) as covariates, and the 15
BNF Chapters (e.g., skin, eye, cardiovascular system, central
nervous system) as a factor. Given that many chemicals were
launched shortly before 2007 and were still in use in 2007, it was
necessary to deﬁne the “sales volume” as some function of the
number of prescriptions written in the ﬁrst few years after
launch. My deﬁnition was the average number of prescriptions
written per year, averaged over the ﬁrst four years after launch.
The logarithm of the number of prescriptions was taken because
the number of prescriptions is highly skewed. Several statistical
distributions were used to model statistical errors: Weibull, log-
normal, and log-logistic functions, using the “survreg” survival
analysis function in “R” software [20]. The choice of statistical
distribution was assessed by the Akaike information criteria
(AIC) = -2 log-likelihood + 2(P + 1), where P = 2 parameters for
all distributions. Model ﬁtting was performed by backward dele-
tion of nonsigniﬁcant terms to obtain the minimum adequate
model.
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Results
Four hundred ﬁfty-ﬁve drugs (BNF Chemicals) of medium to
high sales volume were launched from the year 1981 onwards.
Of these, 67 were no longer used in primary care in England in
2007 (Table 1), and therefore the lifetimes of these drugs were
not censored for the statistical analysis. The lifetimes of the
remaining 388 drugs were right censored.
Table 1 Lifetimes of the 67 drugs no longer used in primary care in England
BNF Chemical BNF Section Launch year Lifetime (years) Prescriptions (,000s)*
Acid insulin injection Drugs used in diabetes 1983 6 13
Activated dimethicone Antacids and other drugs for dyspepsia 1998 2 179
Adrenaline hydrochloride Treatment of glaucoma 1982 12 2
Almasilate Dyspep & gastroesophageal reﬂux disease 1983 4 18
Alprazolam Hypnotics and anxiolytics 1983 3 105
Amethocaine Local anesthesia 1998 7 6
Aminoglutethimide Sex hormones & antag in malig disease 1982 24 11
Amoxapine Antidepressant drugs 1989 17 16
Astemizole Allergic disorders 1983 18 250
Atenolol with thiazides Beta-adrenoceptor blocking drugs 1997 7 15
Betaxolol hydrochloride Beta-adrenoceptor blocking drugs 1984 20 7
Biphasic insulin injection Drugs used in diabetes 1983 15 13
Bismuth salts Preparations for haemorrhoids 1998 1 307
Bromazepam Hypnotics and anxiolytics 1982 4 49
Catheter patency solutions Drugs for genitourinary disorders 1983 23 15
Ceftibuten Antibacterial drugs 1994 6 15
Cerivastatin Lipid-regulating drugs 1997 6 383
Cimetidine with alginate Ulcer-healing drugs 1989 12 61
Cisapride Antispasmod. & other drugs alt.gut motility 1989 17 100
Cyclofenil Hypothalamic & pituitary hormones & antioest 1982 13 1
Desoximetasone Topical corticosteroids 1984 23 13
Dexfenﬂuramine hydrochloride Drugs used in obesity 1990 8 88
Dextropropoxyphene Analgesics 1982 21 4
Enoxacin Antibacterial drugs 1989 4 4
Fenticonazole nitrate Treatment of vaginal & vulval conditions 1995 8 10
Flosequinan Nit, calc blockers & potassium activators 1992 6 3
Flunitrazepam Hypnotics and anxiolytics 1982 4 84
Formestane Sex hormones & antag in malig disease 1993 10 7
Fosfomycin trometamol Antibacterial drugs 1994 4 6
Guar gum Drugs used in diabetes 1984 21 12
Hydroxyapatite Minerals 1981 23 11
Hydroxyethylcellulose Misc. ophthalmic preparations 1998 8 27
Indoramin hydrochloride Antihypertensive therapy 1998 6 12
Isoconazole nitrate Treatment of vaginal & vulval conditions 1981 20 38
Lactitol Laxatives 1992 11 19
Levocabastine Corti’roids & other antiinﬂamm. preps. 1996 11 10
Loxapine succinate Drugs used in psychoses & rel. disorders 1990 16 7
Magaldrate Dyspep & gastroesophageal reﬂux disease 1984 12 5
Mibefradil Nit, calc blockers & potassium activators 1997 2 10
Oxatomide Antihist, hyposensit & allergic emergen 1982 14 5
Oxitropium bromide Bronchodilators 1991 15 112
Papaverine hydrochloride Drugs for genitourinary disorders 1988 18 2
Pirbuterol acetate Bronchodilators 1983 16 32
Pirbuterol hydrochloride Bronchodilators 1983 14 23
Pirenzepine Antisecretory drugs +mucosal protectants 1982 18 10
Piretanide Diuretics 1984 14 32
Pivampicillin with pivmecillinam Antibacterial drugs 1984 11 124
Pseudoephedrine sulphate combinations Systemic nasal decongestants 1982 9 44
Remoxipride hydrochloride Drugs used in psychoses & rel. disorders 1991 7 8
Reproterol hydrochloride Bronchodilators 1981 21 30
Rofecoxib Drugs used in rheumatic diseases & gout 1999 7 999
Salcatonin Drugs affecting bone metabolism 1998 5 6
Semisodium valporate Drugs used in psychoses & rel. disorders 2001 3 48
Sertindole Drugs used in psychoses & rel. disorders 1996 4 3
Sodium pyrrolidone carboxylate Emollient & barrier preparations 1988 12 6
Somatrem Hypothalamic & pituitary hormones & antioest 1986 5 9
Suprofen Drugs used in rheumatic diseases & gout 1983 4 20
Temaﬂoxacin hydrochloride Antibacterial drugs 1992 1 6
Terfenadine Allergic disorders 1982 22 863
Terodiline hydrochloride Drugs for genitourinary disorders 1986 7 208
Thyroxine sodium Thyroid and antithyroid drugs 1998 5 8804
Tocainide hydrochloride Antiarrhythmic drugs 1982 16 5
Troglitazone Drugs used in diabetes 1997 1 6
Urofollitropin Hypothalamic & pituitary hormones & antioest 1981 20 0
Valdecoxib Drugs used in rheumatic diseases & gout 2003 3 81
Xamoterol fumarate Sympathomimetics 1988 13 18
Yellow fever Vaccines and antisera 1991 2 7
*Average number of prescriptions per year averaged over ﬁrst four years after launch.
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Estimated Drug Lifetimes
Variation in drug lifetimes was best explained by the Weibull
function, as measured by the minimum AIC: AIC-
(Weibull) = 743.2, AIC(lognormal) = 744.8, AIC(log-logistic) =
743.7. Therefore, statistical errors were modeled by a Weibull
distribution. Neither launch year nor BNF Chapter signiﬁcantly
explained any of the variation in drug lifetimes: (c1 = 1.43,
P = 0.23 and c15 = 23.0, P = 0.08, respectively). Nevertheless,
nonsigniﬁcance may be a result of the low statistical power,
because of the high degree of censorship, rather than because of
a true lack of association. Drug lifetimes were signiﬁcantly
(c1 = 7.68, P = 0.006) shorter with lower sales volumes (log(av-
erage number of prescriptions + 1)) (Figs. 2 and 3).
I deﬁne the Weibull shape parameter a and scale parameter
b as in the survival equation: S t
t
b
a
( ) = −( )⎡⎣⎢ ⎤⎦⎥exp . The Weibull
parameters without sales volume as an explanatory variable were
estimated as: shape parameter = a = 1.355, with ln(1/shape) with
mean -0.304 and standard error 0.107 (z = -2.85, P = 0.004),
and scale parameter = b = 60.3 with ln(scale) with mean 4.10
and standard error 0.161, where time is measured in years. The
covariance of ln(1/shape) and ln(scale) is 0.0142.
Next, the following simulation method was used to estimate
the mean and 95% conﬁdence interval (CI) of the lifetime of any
single drug (NB not the CI of the mean lifetime). There are two
types of uncertainty in estimating the lifetime of any single drug:
uncertainty in the Weibull parameters (quantiﬁed from the
regression output above) and uncertainty from sampling from a
Weibull distribution with a given pair of simulated Weibull
parameters. First, 10,000 simulations of ln(1/shape) and ln(scale)
were generated, given that they follow a multivariate normal
distribution with means, variances, and covariance given above.
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Censorships are shown by the short vertical tick marks on the Kaplan-Meier curve. 
Figure 2 Probability drug in use as a function of time from drug launch.The continuous stepped line is the Kaplan–Meier curve with 95% conﬁdence interval shown
by the dashed lines.TheWeibull curve best ﬁt is shown by the smooth narrow line. Figure (b) displays the same information as ﬁgure (a), but with the time axis rescaled
to show the Weibull extrapolation.
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Figure 3 Probability drug in use as a function of time from drug launch for drugs with (a) low† and (b) high sales volume. † “Low sales volume” deﬁned as less than
an average of 47,000 prescriptions written per year over the ﬁrst four years from drug launch, and “high sales volume” deﬁned as greater than 47,000 prescriptions.
The threshold of 47,000 prescriptions was chosen because it is the median value over all 455 drugs analyzed.
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Next, the shape and scale parameters were obtained by back-
transforming from the simulated values. Then, for each simula-
tion, a lifetime value, T, was randomly drawn from a Weibull
distribution with the simulated pair of shape and scale param-
eters. This yielded a mean lifetime of any single drug of 57 years,
with 95% CI of 4 to 173 years. Note that this relies on the
assumption that the distribution of drug lifetimes continues to
follow a Weibull distribution beyond 26 years (Fig. 2b).
Given that it is necessary to generate the values for the
drug lifetime, T, for cost-effectiveness analysis below, I ﬁtted a
Weibull function to the 10,000 simulated values of T. For the
ﬁtting method, see: http://www.ispor.org/Publications/value/
ViHsupplementary/ViH13i8_Hoyle.asp. This yielded shape
parameter = a = 1.28, and scale = b = 60.9 (Fig. 4). Of course,
these parameters are different (but only slightly) to the corre-
sponding mean values above (a = 1.355, b = 60.3), because we
now incorporate uncertainty in the shape and scale parameters.
Now, I calculate the 95% CI of the mean lifetime (i.e., not the
CI of the lifetime of any one drug). The mean of the Weibull
distribution is b
a
Γ 1 1+( ) . Substituting the 10,000 pairs of
simulated shape and scale parameters into this equation to gen-
erate 10,000 mean lifetimes, the 95% CI of the mean lifetime is
39 to 79 years. Next, given that the median of the Weibull
distribution is b aln 2
1
( )[ ] , substituting the simulated shape and
scale parameters into this equation gives an average median
lifetime of 46 years, with 95% CI of 35 to 60 years. The CIs are
wide in part because of the high degree of censoring.
I now consider the model including sales volume as an
explanatory factor, because it signiﬁcantly explained some of the
variability in the drug lifetimes. The Weibull parameters were
estimated as: shape parameter = a = 1.340, with ln(1/shape) with
mean -0.293 and standard error 0.107 (z = -2.75, P = 0.006) and
scale parameter=b= exp[3.64 + 0.139 ln(P+1)] = 38.1(P+1)0.139
where P is the sales volume (in thousands of prescri-
ptions), deﬁned above. This gives a mean lifetime of
38 1 1 1
1
35 10 139 0 139. . .P P+( ) +( ) = +( )Γ 1.340 , and a median of
38 1 1 2 29 10 139
1
1 34
0 139. ln( ). . .P P+( ) [ ] = +( ) .
Application to Value of Information Analysis
For each simulated drug lifetime, the ratio of the popu-
lation EVPI to the single year EVPI (Equation 1) is
1
1 11
1
+( ) =
−
−
=
+∑ r
v v
vtt
T T
, where equal population incidence It is
assumed for each year, r = 3.5% as in England and Wales [10],
and v = 1/(1 + r). The mean of this ratio for individual drugs is
21, with 95% CI of 3.6 to 28. Notice that this mean of 21 does
not equal the factor of 25 calculated at the mean lifetime of
T = 57 years, which is expected because the ratio is a nonlinear
function of T. Next, the mean ratio given the mean lifetime of
T = 57 (39–79) is 24, with 95% CI of 21 to 27 (Fig. 1).
Application to Cost-Effectiveness Analysis
Next, I apply the estimates of drug lifetimes to the cost-
effectiveness methodology of Hoyle and Anderson [15]. Suppose
the cost and beneﬁt discount rates differ (e.g., for The Nether-
lands, where costs are discounted at 4% per year and beneﬁts at
1.5% per year) [21]. Suppose the prevalent cohort is small rela-
tive to the incident cohorts (e.g., a drug for an acute condition).
Then, cost-effectiveness should be based on all future incident
cohorts [15], and can be approximated by Equation 3a. For each
of the 10,000 simulated drug lifetimes T, the factor
1
1
1
1
1
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−
−
⎛⎝ ⎞⎠ −
−
⎛⎝⎜ ⎞⎠⎟
+
+
v
v
v
v
T
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(Equation 3a), used to convert the ICER
assuming a single incident cohort into the ICER assuming mul-
tiple incident cohorts, was calculated. The mean of this factor is
0.66, with 95% CI of 0.42 to 0.96. Notice that this mean of 0.66
does not equal the factor of 0.60 calculated at the mean lifetime
of T = 57 years, which is expected because the factor is a non-
linear function of T. Next, the mean factor given the mean
lifetime of T = 57 (39–79) is 0.60, with 95% CI of 0.53 to 0.68.
For the probabilistic sensitivity analysis, it is necessary to
model the variability in the net beneﬁt, and therefore the
total costs and beneﬁts when modeling all future incident
cohorts. In Equation 3b, T can be modeled as a Weibull
distribution with shape parameter = a = 1.28, and scale
parameter = b = 60.9. For The Netherlands, this gives mean
factors of 1
1
19 7 95 5 26
1
−
−
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+v
v
T
C
C
CI. % and
1
1
1
−
−
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+v
v
T
B
B
33 6 95 5 62. % CI −( ).
Now, suppose the prevalent cohort is large relative to the
incident cohort (e.g., for a drug for a chronic condition). Then,
even when the cost and beneﬁt discount rates are equal, cost-
effectiveness should be based on the prevalent and all future
incident cohorts [15]. When costs and beneﬁts are both
discounted at 3.5% per year, as in the UK [10],
1
1
21 5 95 5 29
1
−
−
⎛⎝⎜ ⎞⎠⎟ = −( )
+v
v
T
. % CI .
Discussion
Drug Lifetimes
I recommend that the lifetimes of drugs in England in the future
can be modeled by a Weibull distribution with shape param-
eter = 1.28 and scale parameter = 60.9, giving a mean lifetime of
57 years. The mean lifetime is broadly consistent with the ﬁnd-
ings of Danzon and Kim [1], who state that the sales volume of
global chemicals on average peaked at about 20 to 30 years in the
UK over the period 1981 to 1992. The estimates of the mean and
median drug lifetimes in this study are subject to a large amount
of uncertainty, because of the immaturity of the survival data.
The estimate of the median drug lifetime averaged over all drugs
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Figure 4 Probability density function of the historical lifetimes of drugs. The
Weibull best ﬁt is shown by the continuous line.
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of 46 years (95% CI 35–60 years) is more accurate than the mean
lifetime of 57 years (95% CI 39–79 years) because the mean is
inﬂuenced by the shape of the tail of the distribution of lifetimes,
which is highly uncertain, given the immaturity of the empirical
data. There are two possibilities for gathering more information
to inform drug lifetimes and therefore to reduce the uncertainty.
First, this analysis could be repeated several years in the future
when more data from the Prescription Cost Analysis for England
database [17] is available. Second, it would be useful to obtain
information on lifetimes of drugs that were launched before
1981. Nevertheless, I was unable to obtain such data from the
Medicines and Healthcare products Regulatory Agency in the
UK.
Drugs with lower sales volumes tended to have shorter life-
times. This seems intuitively plausible, because the sales volumes
of some drugs may be low because they are out-competed by one
or more superior drugs. Of course, the sales volumes of some
drugs will be low if they are designed to treat a rare condition. In
this case, there seems to be no reason why the lifetimes of such
drugs should be shorter than the average. There was no evidence
for differences in drug lifetimes according to BNF Chapter. There
may indeed be little variation in drug lifetimes by therapeutic
category, or there may actually be some variation, but this analy-
sis was insufﬁciently powered to detect it because of the high
degree of censorship.
This study is statistical, and I do not investigate the factors
that inﬂuence the lifetimes of individual drugs. Nevertheless, it is
well known that the volume of individual drugs sold declines as
newer, more effective drugs are launched [1,2]. Also, the lifetimes
of some drugs are short because they are withdrawn from the
market by the manufacturer because of serious side effects dis-
covered soon after launch (e.g., cerivastatin [22], mibefradil [23],
rofecoxib [24]).
Value of Information
For expected value of information analysis, we are interested
only in the expected ratio of the population EVPI to the single
year EVPI, estimated as 21, not the variability of the value of
information, estimated as 95% CI 3.6 to 28. Notably, the mean
ratio of 21 is large, which reminds us that the information time
horizon is a very important determinant of population level
expected value of information.
The time horizon, T, is not the only factor that is uncertain in
estimating population EVPI. For example, Equation 1 above
assumes that the per-episode EVPI will stay constant in the
future. Nevertheless, the per-episode EVPI may not stay constant
if, for example, the price of a new technology changes over time,
or if a new technology enters the market which treats the same
condition [12]. To illustrate the ﬁrst example, suppose that a
drug is on patent for the ﬁrst 10 years after launch, and suppose
it is cost-effective in the ﬁrst year. Now suppose the price of the
drug falls at year 11, when the drug comes off patent. Then, the
per-episode EVPI falls [12]. Nevertheless, it is in theory possible
to model the per-episode EVPI after patient expiry, given
assumptions for the time to patent expiry and the price drop at
patent expiry. Concerning the second example, suppose a new
technology enters the market 10 years in the future, which is
more effective and has lower costs than the existing technology.
Then, the per-episode partial EVPI for the original set of param-
eters falls, but the per-episode partial EVPI for all parameters,
including those for the new technology, may remain reasonably
high [12]. In this case, the estimated lifetime of drugs calculated
in this study could be used to estimate the partial EVPI for the
original set of parameters, but not for all parameters.
Some drugs are used to treat more than one condition. Nev-
ertheless, for the purposes of cost-effectiveness analysis [2–15]
and the time horizon T for value of information for parameters
concerning the treatment effect of a drug, we are interested in the
lifetime of the drug for treating only one condition. For example,
suppose the parameter q represents the treatment effectiveness of
a drug used to treat a certain condition. The appropriate time
horizon for value of information concerning q should therefore
relate to the lifetime of the drug used to treat this condition only.
In this case, estimates of T obtained in this analysis may be
slightly overestimated. On the other hand, if we are concerned
with the value of information of a parameter applicable to a drug
used to treat more than one condition, such as the side effects of
the drug, then the expected lifetime of the drug may be an
appropriate time horizon.
Cost-Effectiveness Analysis
To model multiple incident cohorts, the mean of the factor in
Equation 3a should be used to estimate the deterministic ICER
when the cost and beneﬁt discount rates differ. In The Nether-
lands, where costs are discounted at 4% per year and beneﬁts at
1.5% per year [21], this factor is 0.66. Under this methodology,
cost-effectiveness appears substantially better than under the tra-
ditional method of modeling just a single incident cohort. Most
economists argue that the cost and beneﬁt discount rates should
be equal [25], and this is the case in most countries [21]. Never-
theless, some economists disagree [25–27].
To calculate net beneﬁt for the probabilistic sensitivity analy-
sis, I recommend that total discounted costs and beneﬁts over all
incident cohorts should be calculated as in Equation 3b, with the
time horizon T modeled as a Weibull distribution with shape
parameter = 1.28 and scale parameter = 60.9. When costs and
beneﬁts are both discounted at 3.5% per year, as in the UK [10],
1
1
21 5 95 5 29
1
−
−
⎛⎝⎜ ⎞⎠⎟ = −( )
+v
v
T
. % CI . Total costs and beneﬁts are
therefore substantially greater when we model all future incident
cohorts than the traditional method of modeling just a single
incident cohort.
The costs and beneﬁts in all future incident cohorts are
assumed equal [15]. This assumption would be violated if, for
example, one component of the costs is predicted to increase in
the future at a different rate to the other components. Neverthe-
less, we can allow for this by suitable adjustment of Equations 2
and 3.
Now, turning to the cost-effectiveness framework of Salomon
et al. [2]. The estimates of the lifetimes of drugs in this study can
be used to estimate the year of introduction of a new technology
B (see Introduction). Nevertheless, the cost and effectiveness of
the new technology B are likely to be uncertain, and these param-
eters are central to this framework.
Assumptions of Methodology and Applicability to
Other Countries
The data underlying this study were for drugs used in primary
care only, not in hospitals. Nevertheless, I believe that had I
analyzed the number of prescriptions for drugs used in hospitals,
as well as in primary care, a similar estimate of mean drug
lifetime would have been obtained. First, prescriptions written by
general medical practitioners in England account for the great
majority, 75%, of pharmaceutical expenditure in the NHS [18].
Second, it seems reasonable to assume that the launch dates of
any given drug in primary and secondary care are similar, and
that the dates when the drug ceases to be used are also similar.
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Nonetheless, the lifetime of any given drug in both primary and
secondary care will clearly be at least as great as the lifetime in
primary care alone. Therefore, the mean and median drug life-
times estimated here may slightly underestimate the lifetimes of
drugs in the UK National Health Service as a whole.
The estimates of drug lifetimes in this study are useful in
informing the time horizon for value of information and for
cost-effectiveness analyses only if the lifetimes of drugs in the
future are similar to those in the past. Nevertheless, the drug
regulatory and market environments in England will doubtless
change over time, and this may alter the mean drug lifetimes.
Nonetheless, on an optimistic note, there was no evidence that
the mean lifetime of drugs has changed over time in the past,
although, of course, we must wait many years to have an accu-
rate assessment of the lifetimes of drug launched in the recent
past.
This analysis concerns drugs in England. Given differences in
the drug regulatory and market environments in England com-
pared with other countries, the relevance of the drug lifetimes
from this study to other countries is unclear. Nevertheless,
Danzon and Kim [1] found that the proﬁle of the volumes of drug
sales as a function of time since launch is reasonably similar
across the countries analyzed: Canada, Germany, France, Italy,
Japan, and United States, with some evidence that drug sales
peak slightly later in the UK. This suggests that drug lifetimes in
other countries may be slightly shorter than those presented in
this study.
In summary, I ﬁnd that the historical lifetimes of drugs in
England can be modeled as a Weibull distribution with a mean of
57 years and median of 46 years. Using this information to
project into the future, and under certain assumptions, when the
discount rate is 3.5%, the PEVPI is 21 times the per-year value
of information. I have demonstrated how the historical lifetimes
of drugs can inform two models of cost-effectiveness.
I thank an anonymous referee who helped to improve this article.
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